GlassScriptPhysician profile
Christina M Mitsdarffer
NPI 1639530298
$1,369.75
in general payments reported to CMS, 2019-2025
27 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $178 · 2023: $554 · 2024: $369 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.05 | 2022-2025 | |
| Csl Behring | $128.71 | 2021-2025 | Hizentra |
| Ucb, INC. | $96.88 | 2024-2025 | Fintepla |
| Alexion Pharmaceuticals, INC. | $83.40 | 2022-2024 | Soliris |
| Teva Pharmaceuticals USA, INC. | $69.51 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $54.65 | 2023-2024 | |
| Genentech USA, INC. | $53.41 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $49.04 | 2022-2023 | Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $41.76 | 2022-2023 | Gammagard |
| Astrazeneca Pharmaceuticals LP | $39.68 | 2021-2024 | Wainua |
| Acorda Therapeutics, INC | $37.92 | 2023 | Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $37.88 | 2023 | |
| Medtronic, INC. | $37.79 | 2022-2023 | Linq II |
| Neurelis, INC. | $34.06 | 2023 | Valtoco |
| Lilly USA, LLC | $33.48 | 2023-2024 | Emgality, Reyvow, Amyvid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $31.68 | 2025 | Cala Kiq |
| Janssen Pharmaceuticals, INC | $27.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $26.93 | 2023 | |
| Microtransponder, INC. | $23.73 | 2024 | |
| Mylan Specialty L.P. | $23.39 | 2021 | |
| Kyowa Kirin, INC. | $21.88 | 2024 | Nourianz |
| Cycle Pharmaceuticals INC | $19.48 | 2024 | Tascenso Odt |
| Tanabe Pharma America, INC. | $18.05 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2023 | Nuedexta |
| Boston Scientific Corporation | $15.48 | 2023 | |
| Paratek Pharmaceuticals, INC. | $12.55 | 2021 | |
| Novo Nordisk INC | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Mitsdarffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.